ClinicalTrials.gg
Status unknownNCT05495620Updated Aug 10, 2022

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

An observational study in Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Dong-A University Hospital. Status unknown. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Dong-A University Hospital · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
19 Years and older
Sex
All
01

Study summary

Research question: Is KRd therapy effective and safe in the real-world Asian patients?

Primay objective: To evaluate the effectiveness of KRd in RRMM patients

Secondary objectives:

To evaluate the effectiveness of investigational treatment strategy by

  • PFS difference according to the high-risk disease subgroups and previous treatment
  • OS
  • Overall response rate and clinical benefit rate
  • Duration of response To evaluate the safety and tolerability of KRd in RRMM patients
Read the detailed description

Key study variables:

Demographic data, ISS, R-ISS, cytogenetic abnormalities on FISH and G-banding, previous treatment regimens, response to previous treatment regimens, existence of extramedullary plasmacytoma, MM-related symptoms, whether or not M protein has increased twice or more in 2-3 months at the time of KRd commencement, response to KRd therapy, duration of KRd treatment, adverse events during KRd therapy, disease progression and progression date, survival, and censored date or day of death

02

Conditions studied

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Browse trials for

03

In context

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

This study's planned enrollment of 300 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Dong-A University Hospital is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Relapsed and/or refractory multiple myeloma patients treated with carfilzomib-lenalidomide-dexamethasone combination chemotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 19 years
  2. multiple myeloma patients
  3. Patients who had received KRd combination chemotherapy from February, 2018 to February, 2020.

Exclusion criteria

Exclusion criteria

  1. Patient who had not been treated with KRd combination therapy from the first cycle of treatment
  2. Patients who had received KRd combination chemotherapy before February, 2018 and after February, 2020.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Relapsed and/or refractory multiple myeloma

    Multiple myeloma in relapsed but not refractory, relapsed and refractory, and primary refractory status

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    the time from the first date of KRd to the date of disease progression or death or censored date

    Time frame: up to 54 months

Secondary outcomes

  1. Overall survival

    the time from the first date of KRd treatment to the time of death or censored date

    Time frame: up to 54 months

  2. Overall response rate, clinical benefit rate

    the proportion of patients who achieved a PR or better, which response is defined by the IMWG criteria, the proportion of patients who achieved a MR or better

    Time frame: up to 54 months

  3. Duration of response

    the time from the first date of response to the time of disease progression or death or censored date

    Time frame: up to 54 months

  4. Toxicity profile

    toxicities as determined by the incidence of clinical and laboratory findings occurred from the time of the first date of KRd treatment to the date of disease progression or death or censored date

    Time frame: up to 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. PubMed 25482145 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2022; primary completion for Jan 2023, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Aug 10, 2022
StartEst.
Aug 1, 2022
Primary completionEst.
Jan 31, 2023
CompletionEst.
Sep 30, 2023
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05495620
Lead sponsor
Dong-A University Hospital
Collaborators
Amgen
Responsible party
Sung-Hyun Kim (Professor, Dong-A University Hospital) — Principal investigator
First posted
Aug 10, 2022
Start date
Aug 1, 2022 (estimated)
Primary completion
Jan 31, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Aug 10, 2022

Study contacts

Ji Hyun Lee, MD, Ph.D
Contact
hidrleejh@dau.ac.kr
82-51-240-2915
Sung-Hyun Kim, MD, Ph.D
principal investigator · Dong-A University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion